Pharmaceutical Industry in
Basel
251 companies in Pharmaceutical Industry based in Basel — name and year of registration from the commercial register.
50 of 251 companies
Doetsch Grether AG
Since 1996 · 51–100 empl.5.0(4)
Doetsch Grether AG is a healthcare company that develops, markets and distributes brands and products in the pharmaceutical, OTC and consumer care sectors. The company manages a portfolio of proprietary and exclusive international brands, supplies pharmacies, drugstores and retail, and organises its operations into the business units Consumer Health, Pharma and Vita Health Care.
Solvias AG
Since 2011 · 21–50 empl.4.4(23)
Solvias AG is a contract research organization focused on CMC analytical services for pharmaceutical and biopharmaceutical development. The company provides services including analytical method development and validation, analytical characterization, stability testing, biosafety testing, and cGMP testing and release of drug substances and drug products.
Lonza Group AG
Since 2002 · 101–500 empl.4.6(5)
Lonza Group AG is a CDMO company serving the healthcare industry, providing development and manufacturing services for biologics, small molecules and specialized modalities. The company supports customers with integrated offerings from early development through commercial production, as well as regulatory services.
Hoffmann - La Roche Ltd
Since 1946 · 500+ empl.3.8(10)
Hoffmann - La Roche Ltd entwickelt Arzneimittel, In-vitro-Diagnostika und digitale Gesundheitslösungen und betreibt Forschung sowie Produktentwicklung in den Bereichen Pharma und Diagnostik.
Eumedica Pharmaceuticals AG
Since 1995 · 21–50 empl.4.6(5)
The core activity of Eumedica Pharmaceuticals AG is the development, manufacture and marketing of pharmaceuticals, particularly established products for rare and severe diseases. The company focuses on addressing critical unmet medical needs and offers a broad range of therapeutic solutions distributed in over 36 countries.
Celonic AG
Since 2011 · 101–500 empl.3.5(11)
The core activity of Celonic is the development and manufacture of biologics as a Contract Development and Manufacturing Organization (CDMO). The company offers services in the areas of preclinical development, clinical supply, late-stage and commercial supply, and has locations in Basel, Switzerland, and Heidelberg, Germany.
Latscha Schöllhorn Partner AG
Since 2012 · 11–20 empl.4.2(5)
The company's core activity is the development and implementation of biopharmaceutical compounds and targeted immunotherapies for the treatment and prevention of chronic diseases, as well as the development and management of patents and intellectual property in the fields of biotechnology, pharmaceuticals and medical technology.
Boehringer Ingelheim (Schweiz) GmbH
Since 1957 · 1–10 empl.
Boehringer Ingelheim (Schweiz) GmbH is a research-driven pharmaceutical company that develops, manufactures and markets medicines and health care products for humans and animals. Its core activities include human health, animal health, research and innovation, and collaboration in the life sciences sector.
Roche Chemische Unternehmungen AG
Since 1958 · 101–500 empl.
Roche Chemische Unternehmungen AG is a healthcare company that combines diagnostics, medicines and digital solutions. In Switzerland, it develops and provides diagnostic solutions and medicines, and supports healthcare professionals and institutions.
Novartis Foundation
Since 1979 · 11–20 empl.
The core activity of Novartis is the development, manufacture and marketing of pharmaceuticals and healthcare products, with a focus on innovation and access to healthcare, particularly in the areas of malaria, neglected tropical diseases and non-communicable diseases such as sickle cell anemia.
Salmon Pharma GmbH
Since 1982 · 1–10 empl.
The company's core activity is the development, production and distribution of pharmaceuticals, particularly in the areas of ADHD, anemia, nephrology and urology. The company specializes in the manufacture of medications that aim to improve the quality of life for patients.
Nutrimed AG
Since 1986 · 1–10 empl.
The core activity of Nutrimed LTD is the development, manufacture and marketing of dietary supplements, particularly vitamins and minerals such as magnesium, vitamin B12, vitamin D and zinc, in various forms such as effervescent tablets and soft capsules.
Novartis Stiftung für Mensch und Umwelt
Since 1989 · 11–20 empl.
Novartis Stiftung für Mensch und Umwelt supports Novartis’ social and environmental initiatives, including sponsorship, donations and community engagement. The foundation also addresses health, safety and environmental protection measures and promotes transparency in ethics and compliance.
Rhenochem AG
Since 1990 · 101–500 empl.
Rhenochem AG is a pharmaceutical company offering distribution and sourcing of active pharmaceutical ingredients and finished formulations, together with contract manufacturing and technology transfer. Its services include regulatory support, pharmaceutical logistics, financing assistance and market intelligence.
Dispopharm Services GmbH
Since 1994 · 1–10 empl.
The core activity of Dispopharm Services is the provision of pharmaceutical and healthcare services.
Elanco Tiergesundheit AG
Since 1997 · 21–50 empl.
The core activity of Elanco is the development and manufacture of animal health medicines and products that improve the health, well-being and performance of animals, as well as providing services and solutions for animal health.
Pierre Fabre Pharma SA
Since 1997 · 21–50 empl.
The core activity of Pierre Fabre encompasses the development, manufacture and marketing of products in the field of dermatology and cosmetics, including ethical medicines, over-the-counter medications and dermo-cosmetic products.
ICON Clinical Research (Switzerland) GmbH
Since 1998 · 11–20 empl.
The company ICON is a service provider to the pharmaceutical industry, focusing on clinical research, medical communication, and market access. The core activities include: * Clinical Research: Conducting clinical trials, including decentralized clinical trials, early-phase studies, and bioanalysis * Medical Communication: Creating medical content, such as publications, presentations, and marketing materials * Market Access: Supporting pharmaceutical companies in launching medicines, including health economics, outcomes research, and market research * Laboratory Services: Bioanalysis, biomarker development and analysis, as well as other laboratory services * Consulting: Strategic consulting for pharmaceutical companies in the areas of clinical research, market access, and medical communication The company also offers specialized services such as risk management, safety reporting, and regulatory affairs.
Mundipharma Medical Company, Hamilton, Bermuda, Basel Branch
Since 2001 · 101–500 empl.
The core activity of Mundipharma is the development, manufacture and marketing of pharmaceutical products, particularly in the field of pain management for cancer patients.
PharmaMar AG
Since 2001 · 11–20 empl.
The core activity of PharmaMar is the development and marketing of cancer drugs, particularly marine-derived oncology therapies. The company researches and develops innovative treatments for cancer patients and offers products such as Yondelis, Zepzelca and Aplidin.
Bayer Consumer Care AG
Since 2005 · 51–100 empl.
Bayer Consumer Care AG is a life science company active in healthcare and agriculture. The company develops and markets products and solutions for human health and agricultural production.
Mundipharma Distribution GmbH
Since 2005 · 1–10 empl.
HetCat PD Dr. Reza Fallahpour
Since 2005 · 1–10 empl.
HetCat PD Dr. Reza Fallahpour is a chemical services provider supplying heterocyclic and aromatic intermediates, metal catalysts, ligands and inorganic salts through an extensive product catalog. The company also offers custom synthesis and contract research from mg to kg scale, including process development, scale‑up and logistics support.
Luye Pharma Switzerland AG
Since 2006 · 11–20 empl.
Luye Pharma Switzerland AG is a pharmaceutical company that develops and manufactures transdermal drug patches and provides CDMO and contract manufacturing services. Its offerings include formulation development and feasibility studies, scale‑up to production, packaging, regulatory support and licensing solutions.
Pierre Fabre (Suisse) S.A.
Since 2006 · 21–50 empl.
The core activity of Pierre Fabre encompasses the development and manufacture of pharmaceuticals and dermo-cosmetic products, particularly in the fields of oncology, skin care and women's health. The company focuses on developing innovative prescription medicines and dermocosmetic treatments to promote self-esteem and alleviate side effects in cancer patients.
Dr. Reddy's Laboratories SA
Since 2007 · 21–50 empl.
The company's core activity is the development, manufacture and marketing of pharmaceutical products, including generics, biosimilars, over-the-counter products and innovative medicines for various therapeutic areas such as gastroenterology, cardiology, diabetology, oncology, pain management and dermatology.
Rhenopharma AG
Since 2008 · 51–100 empl.
The company's core activity is the development, production, packaging and distribution of pharmaceutical products and services, particularly in the field of healthcare. The company offers integrated, customized services and solutions for the pharmaceutical industry, including "Supply Chain as a Service", to increase efficiency, profitability and patient care on a global scale.
Vaximm AG
Since 2008 · 1–10 empl.
The core activity of VAXIMM is the development of oral T-cell immunotherapies for cancer patients.
BioVersys AG
Since 2008 · 21–50 empl.
The core activity of Bioversys AG is the development and manufacture of pharmaceuticals, particularly in the field of antibiotic research and the development of therapeutics for various diseases. The company is engaged in the research and development of small molecules, peptides and therapeutic polymers and has experts in the fields of medicinal chemistry, CMC (Chemistry, Manufacturing, Control) and biotechnology on its team.
Rhizen Pharmaceuticals AG
Since 2008 · 51–100 empl.
The core activity of Rhizen Pharmaceuticals AG is the development and marketing of pharmaceuticals, particularly in the field of oncology (cancer treatment) and onco-supportive care. The company focuses on the discovery, development and commercialization of innovative pharmaceuticals that address multiple cancer indications. It has a deep pipeline of assets covering various oncology indications and has expertise in discovery, preclinical development, clinical development and regulatory affairs.
Noorik Biopharmaceuticals AG
Since 2010 · 1–10 empl.
Noorik Biopharmaceuticals AG is a privately owned drug development company focused on repurposing existing drugs and conducting research and development. It is developing a micro-dose formulation of ambrisentan, an endothelin receptor antagonist, for indications including severe COVID-19 pneumonia, portal hypertension and pulmonary arterial hypertension, and has developed novel oral and parenteral formulations, holds second medical use patents and is seeking co-development partners.
Rheinbrands GmbH
Since 2011 · 1–10 empl.
The core activity of RheinBrands GmbH is the development and distribution of innovative consumer healthcare products, particularly in the area of intimate care and wellness products, condoms, medical lubricants and other products for a healthy, clean and hygienic intimate area.
Ironwood Pharmaceuticals GmbH
Since 2012 · 21–50 empl.
The core activity of Ironwood is the development and manufacture of pharmaceutical products, particularly the research and development of therapeutics for various diseases and health conditions.
NBE-Therapeutics AG
Since 2012 · 21–50 empl.
The core activity of NBE-Therapeutics AG is the development and research of therapeutics, particularly in the field of cancer treatment. The company focuses on the development of antibody-drug conjugates (ADCs) and other therapeutics targeting the fight against cancer cells.
Amyra Biotech AG
Since 2013 · 1–10 empl.
The core activity of AMYRA Biotech is the development and research of Brush Border Enzyme Supplementation Technology (BBEST), particularly for the treatment of general health and nutrition issues, food intolerances and gastrointestinal diseases through the supplementation of enzymes found in the small intestine mucosa.
Mundipharma MEA GmbH
Since 2013 · 1–10 empl.
Mundipharma MEA GmbH is a pharmaceutical company that markets medicines and healthcare products and provides medical information. The company operates pharmacovigilance reporting for side effects and maintains contact channels for media and careers; the website references products such as Betadina and Hedrin.
Mundipharma Near East GmbH
Since 2014 · 101–500 empl.
Mundipharma Near East GmbH develops and markets pharmaceutical products with a focus on cancer pain management and other specialty care therapeutic areas.
Swedish Orphan Biovitrum AG
Since 2014 · 101–500 empl.
The company develops and distributes innovative treatments for rare diseases, particularly in the field of hematology, such as hemophilia and immune thrombocytopenia (ITP). The focus is on improving the lives of patients through access to new therapies and promoting patient-centricity and engagement.
Accense S.A.
Since 2014 · 11–20 empl.
The core activity of Accense is the acquisition, development and marketing of pharmaceutical products, in particular those abandoned by large pharmaceutical companies. The company focuses on reviving and marketing established, safe and effective medicines that are useful for public health. Products include Postafen, Agyrax and Navidoxine, which are distributed in various countries such as France, Scandinavia, Malta and the USA.
Acadia Pharmaceuticals GmbH
Since 2014 · 21–50 empl.
The core activity of Acadia Pharmaceuticals is the development, manufacture and marketing of pharmaceuticals, particularly in the field of neuroscience and rare diseases.
NOUSCOM AG
Since 2015 · 21–50 empl.
The core activity of Nouscom is the development of cancer vaccines, in particular neoantigen-based cancer vaccines for tumors with microsatellite instability.
ABBA Therapeutics AG
Since 2015 · 1–10 empl.
ABBA Therapeutics AG is a biopharmaceutical company specialized in mechanisms of cancer and the development of novel antibody medicines for cancer immunotherapy. The company researches protein targets related to immune checkpoints and develops therapeutic antibodies; a PCT patent application has been submitted for antibodies against one of its targets.
TargImmune Therapeutics AG
Since 2016 · 1–10 empl.
The core activity of TargImmune Therapeutics AG is the development and research of oncological compounds and the development of a modular, synthetic, targeted platform technology for nucleic acid therapy. In particular, the company focuses on the development of targeted apoptosis and immunomodulators (TAIMs) that use synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly to the target. The goal is to selectively destroy cancer cells by mimicking natural processes.
Ultragenyx Europe GmbH
Since 2016 · 11–20 empl.
Ultragenyx Europe GmbH is a biopharmaceutical company that develops therapies for rare and ultra-rare genetic diseases and researches multiple drug modalities, including gene therapy. The company maintains a clinical pipeline, provides approved medicines such as DOJOLVI and MEPSEVII, and operates patient support programs.
Selmod GmbH
Since 2016 · 11–20 empl.
The core activity of Selmod is the development of innovative antibiotics for the treatment of life-threatening, multi-resistant infections. The focus is on the discovery and early clinical development of small molecules and peptides against new target molecules or new mechanisms of action on established or validated target molecules.
Luye Pharma Europe AG
Since 2016 · 51–100 empl.
Luye Pharma Europe AG develops and manufactures transdermal therapeutic systems (TTS) and provides CDMO services such as contract development, contract manufacturing, procurement, packaging and regulatory support.
Sumitomo Pharma Switzerland GmbH
Since 2016 · 21–50 empl.
The company's core activity is the development and improvement of healthcare worldwide through innovative research and development, particularly in the fields of biopharmaceuticals and health technology.
Urovant Sciences GmbH
Since 2016 · 1–10 empl.
Urovant Sciences GmbH is a pharmaceutical company focused on research, development and commercialization of therapies in urology, including treatments for overactive bladder such as Vibegron.
EsoCap AG
Since 2017 · 11–20 empl.
The core activity of EsoCap Biotech is the development of medical solutions for esophageal diseases. The company focuses on the clinical development of products and technologies to improve the quality of life for patients with esophageal diseases.
Versameb AG
Since 2017 · 11–20 empl.
The core activity of Versameb is the development of therapeutic solutions, particularly in the fields of dermatology, oncology and mycology, based on a proprietary platform technology.
Pharmaceutical Industry in Basel
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Largest places
Riehen9Pharmaceutical Industry in other places
By canton